These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16651630)

  • 1. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
    Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
    J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.
    Olofsson A; Willén H; Göransson M; Engström K; Meis-Kindblom JM; Stenman G; Kindblom LG; Aman P
    Int J Oncol; 2004 Nov; 25(5):1349-55. PubMed ID: 15492825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
    Bento C; Andersson MK; Aman P
    BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
    Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
    J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDIT3 Expression in Liposarcoma Development.
    Kåbjörn Gustafsson C; Engström K; Aman P
    Sarcoma; 2014; 2014():954671. PubMed ID: 24790523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 11. Requirement for YAP1 signaling in myxoid liposarcoma.
    Trautmann M; Cheng YY; Jensen P; Azoitei N; Brunner I; Hüllein J; Slabicki M; Isfort I; Cyra M; Berthold R; Wardelmann E; Huss S; Altvater B; Rossig C; Hafner S; Simmet T; Ståhlberg A; Åman P; Zenz T; Lange U; Kindler T; Scholl C; Hartmann W; Fröhling S
    EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 30898787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas.
    Huang HY; Antonescu CR
    Ultrastruct Pathol; 2003; 27(4):217-26. PubMed ID: 12907366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paratesticular myxoid/round cell liposarcoma harboring type 3 DDIT3-FUS fusion gene: report of a very rare case.
    Zozumi M; Nakai M; Matsuda I; Hao H; Tsukamoto Y; Shiraishi Y; Nojima M; Yamamoto S; Hirota S
    Pathol Res Pract; 2013 Feb; 209(2):124-7. PubMed ID: 23276404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.
    Rodriguez R; Tornin J; Suarez C; Astudillo A; Rubio R; Yauk C; Williams A; Rosu-Myles M; Funes JM; Boshoff C; Menendez P
    Stem Cells; 2013 Oct; 31(10):2061-72. PubMed ID: 23836491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
    Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.
    Oikawa K; Tanaka M; Itoh S; Takanashi M; Ozaki T; Muragaki Y; Kuroda M
    Br J Cancer; 2012 Jun; 106(12):1976-9. PubMed ID: 22588557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
    Riggi N; Cironi L; Provero P; Suvà ML; Stehle JC; Baumer K; Guillou L; Stamenkovic I
    Cancer Res; 2006 Jul; 66(14):7016-23. PubMed ID: 16849546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies.
    Thelin-Järnum S; Göransson M; Burguete AS; Olofsson A; Aman P
    Int J Cancer; 2002 Feb; 97(4):446-50. PubMed ID: 11802205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.
    Ståhlberg A; Kåbjörn Gustafsson C; Engtröm K; Thomsen C; Dolatabadi S; Jonasson E; Li CY; Ruff D; Chen SM; Åman P
    PLoS One; 2014; 9(11):e113110. PubMed ID: 25393000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells.
    Rodriguez R; Rubio R; Gutierrez-Aranda I; Melen GJ; Elosua C; García-Castro J; Menendez P
    Stem Cells; 2011 Feb; 29(2):179-92. PubMed ID: 21732477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.